CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
This article was originally published in The Tan Sheet
Executive Summary
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.